On this episode of Stock Movers: 
- Crypto-Linked stocks including Robinhood (HOOD) and Terawulf (WULF) ended the day higher as bitcoin miners outperform the digital currency as they expand beyond the cryptocurrency and into AI datacenters.
- Getty (GETY) and Shutterstock (SSTK) tumbled after the UK’s Competition and Markets Authority said the pair’s merger may be expected to result in a substantial lessening of competition.
- Apple (AAPL) ended the day on 2025's first record amid signs of stronger-than-expected demand for its latest iPhone lineup, adding to hopes that a long-awaited upgrade cycle could be underway. Over the weekend, an analysis from Counterpoint Research showed the iPhone 17 series outsold the iPhone 16 by 14% over their respective first 10 days on sale in the US and China.
- Zions Bancorp (ZION) led an aftermarket rally in some regional bank stocks including Western Alliance (WAL) after it delivered earnings that saw its profits top analyst estimates despite a $50 million loss from an alleged fraud tied to a commercial real estate investor group in Southern California. The bank reported $222 million of net income on Monday, just beating forecasts. It also charged off $56 million of bad loans in the third quarter, reflecting losses caused by the alleged fraud.

On this episode of Stock Movers:&nbsp; - Crypto-Linked stocks including Robinhood (HOOD) and Terawulf (WULF) ended the day higher as bitcoin miners outperform the digital currency as they expand beyond the cryptocurrency and into AI datacenters. - Getty (GETY) and Shutterstock (SSTK) tumbled after the UK&rsquo;s Competition and Markets Authority said the pair&rsquo;s merger may be expected to result in a substantial lessening of competition. - Apple (AAPL) ended the day on 2025's first record amid signs of stronger-than-expected demand for its latest iPhone lineup, adding to hopes that a long-awaited upgrade cycle could be underway. Over the weekend, an analysis from Counterpoint Research showed the iPhone 17 series outsold the iPhone 16 by 14% over their respective first 10 days on sale in the US and China. - Zions Bancorp (ZION) led an aftermarket rally in some regional bank stocks including Western Alliance (WAL) after it delivered earnings that saw its profits top analyst estimates despite a $50 million loss from an alleged fraud tied to a commercial real estate investor group in Southern California. The bank reported $222 million of net income on Monday, just beating forecasts. It also charged off $56 million of bad loans in the third quarter, reflecting losses caused by the alleged fraud.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Apple Record, Crypto Stock's AI Play, Getty Falls | Stock Movers

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/7ba065d0-9c68-4b10-b72e-b37c016284b3/transcript

On this episode of Stock Movers:
- Shares of Nvidia (NVDA) edge higher in the premarket session as the company agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products.
- Shares of Indian technology services provider Coforge Ltd. (COFORGE IN) declined ahead of the US market open after the company agreed to buy Encora at an enterprise value of $2.35 billion in an all-stock deal, adding artificial intelligence, data and product engineering expertise. Encora’s shareholders, including Advent International and Warburg Pincus, will get about 20% stake in Coforge through a share swap. Coforge will issue 93.8 million shares at 1,815.91 rupees each to shareholders of Encora at equity value of $1.89 billion. The deal is expected to close in six months.
- Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company’s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

On this episode of Stock Movers: - Shares of Nvidia (NVDA) edge higher in the premarket session as the company agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. - Shares of Indian technology services provider Coforge Ltd. (COFORGE IN) declined ahead of the US market open after the company agreed to buy Encora at an enterprise value of $2.35 billion in an all-stock deal, adding artificial intelligence, data and product engineering expertise. Encora&rsquo;s shareholders, including Advent International and Warburg Pincus, will get about 20% stake in Coforge through a share swap. Coforge will issue 93.8 million shares at 1,815.91 rupees each to shareholders of Encora at equity value of $1.89 billion. The deal is expected to close in six months. - Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company&rsquo;s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

Nvidia Agrees to Groq Licensing Deal; India's Coforge Buys Encora; Biohaven Tumbles

On this episode of Stock Movers:
- Shares of Nvidia (NVDA) edge higher in the premarket session as the company takes agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. 
- Shares of Sidus Space (SIDU) rallied as much as 30 percent ahead of the US market open after the Cape Canaveral, Florida-based space and defense tech company announced plans to raise capital through a public offering of its Class A common stock and or pre-funded warrants.
- Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company’s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

On this episode of Stock Movers: - Shares of Nvidia (NVDA) edge higher in the premarket session as the company takes agreed to a licensing deal with artificial intelligence startup Groq, furthering its investments in companies connected to the AI boom and gaining the right to add a new type of technology to its products. - Shares of Sidus Space (SIDU) rallied as much as 30 percent ahead of the US market open after the Cape Canaveral, Florida-based space and defense tech company announced plans to raise capital through a public offering of its Class A common stock and or pre-funded warrants. - Shares of Biohaven (BHVN) fell as much 14 percent in US premarket trading after a mid-stage study of the company&rsquo;s experimental drug BHV-7000 for the treatment of major depressive disorder missed the primary endpoint. Trends favoring BHV-7000 were observed in some clinically relevant subgroups, including participants with more severe depression at screening and baseline, on primary and secondary outcome measures.

Nvidia Edges Higher; Sidus Space Rallies; Biohaven Slips on Study

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/022de151-e912-4b2c-9c2c-b3bf00c914c4/transcript

- Nike (NKE) shares got a boost on Wednesday after a filing showed that Apple CEO Tim Cook purchased $2.95 million worth of shares on Dec. 22. Cook is Nike’s lead independent director and served as a director since 2005, according to the company’s website. The filing shows Cook purchased 50,000 Class B common stock at a weighted average price of $58.97.
- Costco (COST) rose after receiving an upgrade for Christmas, as Northcoast Research analyst Charles Cerankosky raised the recommendation on wholesale giant to buy from neutral. His new price target of $1,100 implies a 29% increase from Tuesday's closing price. Investors who followed Cerankosky's recommendation received a 0% return in the past year, compared with a negative 9.5% return on the shares.
- Dynavax (DVAX) popped after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm’s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.

- Nike (NKE) shares got a boost on Wednesday after a filing showed that Apple CEO Tim Cook purchased $2.95 million worth of shares on Dec. 22. Cook is Nike&rsquo;s lead independent director and served as a director since 2005, according to the company&rsquo;s website. The filing shows Cook purchased 50,000 Class B common stock at a weighted average price of $58.97. - Costco (COST) rose after receiving an upgrade for Christmas, as Northcoast Research analyst Charles Cerankosky raised the recommendation on wholesale giant to buy from neutral. His new price target of $1,100 implies a 29% increase from Tuesday's closing price. Investors who followed Cerankosky's recommendation received a 0% return in the past year, compared with a negative 9.5% return on the shares. - Dynavax (DVAX) popped after Sanofi agreed to buy the small biopharmaceutical firm for about $2.2 billion, as it seeks to expand a vaccines business currently anchored by its flu shot franchise. The French drugmaker will pay $15.50 a share in cash for Dynavax, 39% above the Emeryville, California-based firm&rsquo;s closing price Tuesday. The statement on Wednesday came minutes after Sanofi said the US Food and Drug Administration had surprisingly rejected its experimental multiple sclerosis drug tolebrutinib.

Nike Jumps, Costco Upgraded, Dynavax Soars

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/75459fc1-6a79-4d0a-a10a-b3bd01160eed/transcript

Apple Record, Crypto Stock's AI Play, Getty Falls | Stock Movers

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips